Cowen Starts Kite Pharma (KITE) at Outperform

Go back to Cowen Starts Kite Pharma (KITE) at Outperform

Credit Suisse Starts Kite Pharma (KITE) at Outperform

July 15, 2014 7:46 AM EDT

Credit Suisse initiated coverage on Kite Pharma (NASDAQ: KITE) with an Outperform rating and a price target of $34.00.

Analyst Jason Kantor expressed enthusiasm for the CAR T and immuno-oncology space and the company's unique position in the field and fast-to-market strategy. Lead therapy,... More

Stifel Nicolaus Starts Kite Pharma (KITE) at Buy

July 15, 2014 7:44 AM EDT

Stifel Nicolaus initiated coverage on Kite Pharma (NASDAQ: KITE) with a Buy rating and a price target of $31.00.

For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.

Shares of Kite Pharma closed at $24.05 yesterday.

... More

Jefferies Starts Kite Pharma (KITE) at Buy

July 15, 2014 6:41 AM EDT

Jefferies initiates coverage on Kite Pharma (NASDAQ: KITE) with a Buy rating and a price target of $35.00.

Analyst Biren Amin comments, "KITE shares hold significant promise based on PI/II data with KTE-C19 observing robust responses in... More